Subsequent Events |
6 Months Ended |
|---|---|
Jun. 30, 2025 | |
| Subsequent Events [Abstract] | |
| Subsequent Events |
18. Subsequent Events Equity Subsequent to June 30, 2025, through August 1, 2025, the Company sold 2,525,578 ordinary shares under the Sales Agreement, with HC Wainwright as agent, at an average net price of $0.86 per ordinary share for net proceeds of $2,175. Manufacturing & Supply Agreement On July 29, 2025, the Company's subsidiary, Iterum Therapeutics International Limited (ITIL), entered into a Commercial Manufacturing and Supply Agreement (the ACS Dobfar Agreement) with ACS Dobfar S.p.A, together with its affiliates (ACS Dobfar) for the manufacture and supply of materials for the Company’s approved product, ORLYNVAHTM. |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|